Found: 11
Select item for more details and to access through your institution.
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects.
- Published in:
- QJM: An International Journal of Medicine, 2011, v. 104, n. 11, p. 957
- By:
- Publication type:
- Article
Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Sepsis in cancer patients residing in Zimbabwe: spectrum of bacterial and fungal aetiologies and their antimicrobial susceptibility patterns.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.
- Published in:
- European Journal of Haematology, 2012, v. 89, n. 1, p. 16, doi. 10.1111/j.1600-0609.2012.01788.x
- By:
- Publication type:
- Article
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
- Published in:
- European Journal of Haematology, 2011, v. 86, n. 5, p. 372, doi. 10.1111/j.1600-0609.2011.01599.x
- By:
- Publication type:
- Article
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
- Published in:
- European Journal of Haematology, 2011, v. 86, n. 1, p. 23, doi. 10.1111/j.1600-0609.2010.01533.x
- By:
- Publication type:
- Article
Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma.
- Published in:
- Clinical Pharmacokinetics, 2012, v. 51, n. 12, p. 823, doi. 10.1007/s40262-012-0010-0
- By:
- Publication type:
- Article
Excessive neutrophil recruitment promotes typical T-helper 17 responses in Coronavirus disease 2019 patients.
- Published in:
- PLoS ONE, 2022, v. 17, n. 8, p. 1, doi. 10.1371/journal.pone.0273186
- By:
- Publication type:
- Article
Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial
- Published in:
- British Journal of Haematology, 2011, v. 153, n. 2, p. 212, doi. 10.1111/j.1365-2141.2011.08569.x
- By:
- Publication type:
- Article
The Cost-Effectiveness of Initial Treatment of Multiple Myelomain the U.S. With Bortezomib Plus Melphalan and Prednisone Versus Thalidomide Plus Melphalan and Prednisone or Lenalidomide Plus Melphalan and Prednisone With Continuous Lenalidomide...
- Published in:
- Oncologist, 2013, v. 18, n. 1, p. 27, doi. 10.1634/theoncologist.2011-0380
- By:
- Publication type:
- Article